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Abstract: NF-κB signaling pathways play an important role in the regulation of cellular immune
and stress responses. Aberrant NF-κB activity has been implicated in almost all the steps of cancer
development and many of the direct and indirect contributions of this transcription factor system
for oncogenesis were revealed in the recent years. The indirect contributions affect almost all
hallmarks and enabling characteristics of cancer, but NF-κB can either promote or antagonize these
tumor-supportive functions, thus prohibiting global NF-κB inhibition. The direct effects are due to
mutations of members of the NF-κB system itself. These mutations typically occur in upstream
components that lead to the activation of NF-κB together with further oncogenesis-promoting
signaling pathways. In contrast, mutations of the downstream components, such as the DNA-binding
subunits, contribute to oncogenic transformation by affecting NF-κB-driven transcriptional output
programs. Here, we discuss the features of recently identified oncogenic RelA fusion proteins and the
characterization of pathways that are regulating the transcriptional activity of NF-κB by regulatory
phosphorylations. As NF-κB’s central role in human physiology prohibits its global inhibition,
these auxiliary or cell type-specific NF-κB regulating pathways are potential therapeutic targets.
Keywords: NF-κB; transcription; cancer
1. The NF-κB System
The NF-κB transcription factor system represents an archetypal signaling pathway that is
evolutionary conserved, with core components occurring in insects, cnidarians, and even some
unicellular species [1]. One of its key functions is the induction of the immune system in response
to pathogens and inflammatory stimuli, but NF-κB is also activated by further adverse stimuli,
such as DNA damage and hypoxia [2,3]. The great variety of input signals is reflected by a multitude
of target genes that do not only represent inducers and effectors of the immune system, but also genes
that impact on cell survival, proliferation, and differentiation [4]. A characteristic feature of NF-κB
is the large variety of inducers that utilize a limited set of signal transduction molecules to create
transcriptional output programs that are specifically tailored to suit the particular requirements in
a specific tissue or organ. This conversion of relatively unspecific input signals to highly specific output
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programs is not really understood and employs components of the NF-κB core signaling pathways in
conjunction with multiple auxiliary systems that confer specificity.
2. The Core NF-κB Activation Pathways
Five different NF-κB DNA-binding subunits share a N-terminal NF-κB/Rel homology domain
(RHD), which mediates DNA-binding, dimerization, and the interaction with the inhibitory IκB
proteins, as schematically shown in Figure 1. The C-terminal regions of RELA (also known as p65),
RELB, and REL (also known as c-Rel) contain transactivation domains (TADs), which associate with
further regulatory proteins to trigger mRNA synthesis. The family members NF-κB1 (also known as
p105) and NF-κB2 (also known as p100) are precursor proteins that lack TADs but contain Ankyrin
repeats in their C-terminal regions [5]. These allow for them to function as IκB proteins and to
mediate protein/protein interactions. Either during translation or through phosphorylation-induced
partial proteolysis, the precursors are processed to yield their DNA-binding forms p50 and p52,
respectively [6]. As p50 and p52 also lack TADs, they cannot trigger transcription unless being
associated with a TAD-containing NF-κB family member, suggesting that constitutive binding of p50
or p52 homodimers to κB sites represses transcription [7]. Alternatively, p50 and p52 can activate
transcription upon association with IκB family members, such as Bcl3.
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including the leucine zipper (LZ), the glycine-rich region (GRR), and the death domain (DD) are shown.
The number of amino acids is given for the human proteins.
Activation of NF-κB can proceed by canonical, noncanonical, and the atypical NF-κB activation
pathway [8]. All of the different NF-κB activating pathways ultimately result in the generation of
active, DNA-binding dimers, which were beforehand retained in the cytosol of unstimulated cells by
association with inhibitory IκB proteins.
In the canonical pathway, membrane anchored or cytosolic receptors sense cytokines,
pathogen-associated molecular patterns (PAMPs), or damage-associated molecular patterns
(DAMPs) [9]. Bound receptors self-associate to trigger signaling cascades, which proceed via
posttranslational modifications (PTMs), including phosphorylation and ubiquitination. A variety
of polyubiquitin chains are formed to mediate NF-κB activation including K63-branched and linear
polyubiquitin chains, which are recognized and bound by chain readers such as TAB2 (TGFβ activated
kinase 1/MAP3K7 binding protein 2) and NEMO (NF-κB essential modulator), respectively [10,11].
These events lead to activation of the so-called IKK (IκB kinase) complex, which is composed of the
catalytic subunits IKKα and IKK in association with the scaffold protein NEMO. The activated IKKs
in turn phosphorylate IκBα in order to enable its subsequent tagging with K48-branched ubiquitin
chains. This allows rapid IκBα degradation by the proteasome, allowing nuclear entry, DNA-binding
and transcriptional activity of the dimerized NF-κB DNA-binding subunits [8].
The noncanonical NF-κB pathway is activated in response to a distinct class of stimuli, particularly
in B-cells. The activation of this pathway depends on NF-κB-inducing kinase (NIK) and IKKα,
which mediate C-terminal processing of NF-κB2/p100, thereby allowing for the generation of p52/RelB
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dimers [12]. The noncanonical pathway requires NF-κB-inducing kinase (NIK) and IKKα, and proceeds
with much slower kinetics [13].
The atypical NF-κB pathway is activated by various adverse stimuli, including DNA damage,
and depends on the inducible modification of NEMO by the ubiquitin-related peptide SUMO-1
(small ubiquitin-like modifier 1). This modification process depends on the SUMO E3 ligase
PIASy (protein inhibitor of activated STAT y) [14]. In addition, DNA damage leads to ATM
(Ataxia Telangiectasia mutated)-mediated TRAF6 (TNF receptor associated factor 6) activation and
cIAP1 (cellular inhibitor of apoptosis protein-1) recruitment, which catalyzes monoubiquitination of
NEMO [15]. These modifications ultimately lead to induction of IKK activity, IκBα degradation and
the release of the DNA-binding subunits.
3. Auxiliary NF-κB Regulating Mechanisms
Any given NF-κB activating stimulus does not only activate NF-κB, but it will necessarily
trigger further signaling pathways. These additional pathways show extensive crosstalk to the
NF-κB system at all levels, as elaborated in a number of excellent reviews [16,17]. Furthermore,
any NF-κB activating pathophysiological situation, such as an infection, will elicit a complex mixture of
NF-κB activating agents and receptors, thus leading to NF-κB activation amidst multiple co-regulated
pathways that serve to dampen, trigger, or shape the NF-κB response. As a result of NF-κB activation,
the DNA-binding subunits, released from their inhibitor, will bind to their cognate κB genomic binding
site, which is conventionally a GGGRNNYYCC (R = purine, N = any nucleotide, Y = pyrimidine)
motif [18]. Binding of NF-κB dimers to the genomic κB site is not only dictated by the accessibility of
the site and by interaction with other transcription factors, such as AP1, but also by the composition
of the κB binding sequence. The extensive characterization of NF-κB binding sites by EMSA-seq
(electrophorectic mobility shift assays coupled to sequencing) experiments uncovered the preferred
motifs for the p65/p50, p65/p65, and p65/p52 complexes [19]. For example, p65/p50 dimers
preferentially bind the motif GGGGRTTTCC, while the p65/p52 heterodimer binds to the sequence
NNNGGGGRYTT. Binding specificity is also achieved by the interaction of nuclear NF-κB subunits
with further transcription factors, such as AP1 family members [20], Erg [21], and E2F1 [22].
Moreover, the DNA-binding capacity of NF-κB DNA-binding subunits can also be regulated
in order to achieve a further level of regulation. For example, acetylation of p65 at Lys 221 causes
a conformation change that favours κB DNA binding [23]. Conversely, the DNA-binding activity
can be inhibited upon association of p65 with PIAS1 [24] or by PTMs, such as nitration of Tyr 66
and Tyr 152, or asymmetric dimethylation of Arg 30 [25,26]. The recent years have witnessed
the identification of further PTMs at the DNA-binding subunits. The PhosphositePlus® database
lists 64 different modifications for the p65 subunit and comparable numbers of PTMs for p105 (61),
p100 (49), c-Rel (22), and RelB (20). The DNA-binding subunits are modified by many different
PTMs, including phosphorylation, ubiquitination, SUMO modification, O-GlcNAcylation, and various
types of methylation. This strong increase in PTM site identification is contrasted by our limited
understanding of their physiological function. Several knock-in mouse models have been generated
that started to unravel the physiological roles of the individual PTMs.
4. Functional Analysis of p65 Phosphorylations In Vivo
The importance of individual p65 modification sites has been investigated in various knock-in
mouse models, which are summarized in Figure 2. Published data are available for five different
p65 knock-in mouse models and the observed range of phenotypes is remarkably broad. None of
these mice that are mutated in p65 phosphorylation sites recapitulate the phenotype of RelA-deficient
mice, which show embryonic lethality that is caused by massive liver degeneration with hepatocyte
apoptosis [27]. The first knock-in mouse model was published almost 10 years ago by the laboratory of
Sankar Ghosh [28]. In this animal, the phosphorylated Ser 276 was changed to a non-phosphorylatable
Ala (p65 S276A). Cells isolated from these mice display a significant reduction of NF-κB-dependent
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transcription. Most of the p65 S276A knock-in embryos die at different embryonic days due to
variegated developmental abnormalities in limb or eye formation, which are due to HDAC (histone
deacetylase)-dependent interference with gene expression. Further experiments showed that p50/p65
S276A heterodimers cannot efficiently bind to CBP/p300 and instead recruit HDACs, resulting in
aberrant repression of non-NF-κB-regulated genes through epigenetic mechanisms and the direct
repression of a subset of NF-κB target genes [28]. The recruitment of HDACs requires the DNA-binding
activity of p65, as demonstrated by the creation of a further knock-in mouse model where the
p65 S276A mutant was additionally changed at Arg 274 to Ala, thus creating a non-DNA-binding
p65 S276A/R274A double mutant [28]. These p65 S276A/R274A mice show no variegation of the
phenotype, but die during embryogenesis due to massive hepatocyte apoptosis, thus resembling
the phenotype of p65-deficient mice [27]. While the p65 S276A mice are phosphorylation-deficient,
the p65 S276D knock-in mice express a phosphomimetic form of p65. These animals are viable,
but consistent with an increased transcriptional activity of p65- show elevated expression of
proinflammatory cytokines and chemokines, resulting in a systemic hyperinflammatory phenotype
leading to death 8–20 days after birth. The lethality of the p65 S276D animals could be rescued by
crossing with a strain lacking the TNF receptor 1 (TNFR1) [29], similar to the rescue of RelA-/-/Tnfr-/-
double knockout animals [30]. However, upon aging, the p65 S276D/Tnfr-/- mice develop chronic
keratitis together with elevated expression of inflammatory cytokines in the cornea, leading to
the development of a phenotype that resembles a human disease called keratoconjunctivitis sicca
(“dry eyes”) [29]. In addition, p65 S276D mice show hyperproliferation and dysplasia of the
mouse epidermis [31]. Several mouse mutants were generated for the analysis of phosphorylated
key residues in the C-terminal TADs. Mice harboring the T505A mutation develop normally but
exhibit increased hepatocyte proliferation following damage resulting from carbon tetrachloride
treatment or liver partial hepatectomy [32]. The p65 T505A mice also show an earlier onset of
tumorigenesis in the N-nitrosodiethylamine model of hepatocellular carcinoma, as consistent with
previous data from reconstituted cells, suggesting that Thr 505 phosphorylation functions to suppress
the tumour-promoting functions of p65 [33]. A further knock-in model addressed the relevance of Ser
534 phosphorylation, a site corresponding to the well-studied Ser 536 in human p65. The p65 S534A
mice are born at normal Mendelian ratios and are healthy. Following the injection of lipopolysaccharide
(LPS) they display slightly increased expression of selective NF-κB target genes and a strongly increased
sensitivity to LPS-induced death [34]. The inhibitory activity of p65 Ser534 phosphorylation on NF-κB
activity may also be due to a decreased half-life of the p65 protein, which is a feature that can be
regulated by phosphorylation at Ser 536 and also at Ser 468 [35–37]. A regulatory effect of Ser 468
phosphorylation on the total amount of p65 was also observed in mice where Ser 467 (the mouse
homolog of human p65 Ser 468) was mutated to Ala. This substitution causes reduced de novo
synthesis of the p65 protein by an unexplored mechanism. The reduced p65 levels likely contribute
to diminished TNF-induced expression of a selected group of NF-κB dependent target genes and
also increased TNF-triggered apoptosis [38]. A serendipitous observation was the reduced weight
gain in male p65 S467A mice. Feeding a high fat diet resulted in a strong body weight increase in
wildtype animals, while male p65 S467A mice were partially protected from an increase in body
weight. This phenotype is likely due to the elevated locomotor activity of these animals, but it is
currently completely unclear why this phenotype only occurs in male mice [38]. It will be also very
interesting to study the mechanisms that are underlying this increased locomotor activity, which might
be attributable to NF-κB’s role for the brain [39].
In summary, most of the reports show a stunning biological variability of the p65 knock-in
phenotypes rather than a uniform modulation of NF-κB-mediated transcription. We anticipate that one
DNA-binding subunit can be simultaneously modified at several positions, but the typical modification
patterns must be revealed in future studies. The analysis of further p65 variants that are simultaneously
mutated at several sites will probably reveal a more complete picture of the regulatory potential of the
auxiliary NF-κB regulating pathways.
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5. The Multiple Roles of NF-κB in Cancer
The c ntral position o NF-κB as a signaling hub in human physiology also involves this n twork in
several human ailments, including cancer. A Pubmed search with the keywords “NF-κB” and “cancer”
revealed >17,200 Pubmed entries for this topic. The complex role of NF-κB in cancer can be attributed
to changes in the canonical and noncanonical pathways, and to indirect and direct mechanisms.
The direct contribution of the NF-κB system to cancer was revealed by a number of genetic changes
of NF-κB regulators detected in cancer cells [40]. These changes include mutation, amplification,
and fusion of NF-κB regulators. Constitutive or chronic NF-κB activation can be achieved by
gain-of-function (GOF) mutatio s that lead to continuous signaling to the IKK complex. Alternatively,
the same effect can be achieved by loss-of-function (LOF) mutations disrupting negative regulators,
such as CYLD or A20, which can lead to the inappropriate termination of the NF-κB response.
The indirect contribution of NF-κB is attrib table to the fact that this transcription factor contributes
to the regulation of most (but not all) classical hallmarks of cancer, as defined by the Hanahan and
Weinberg review: sustained proliferative signaling, resistance to cell death, replicative immortality,
induction of angiogenesis, activation of invasion and metastasis, and reprogramming of energy
metabolism [41]. But, also enabling characteristics, such as the acquisition of genome instability and
tumor-promoting inflammation, are processes in which NF-κB-is involved.
5.1. The Indirect Roles of NF-κB in Cancer
In this section we will discuss the indirect roles of NF-κB in cancer by describing its contribution
to the classical hallmarks and enabling characteristics, as schematically depicted in Figure 3.
Many apoptotic stimuli, including the cytokine TNF, ionizing radiation, and chemotherapeutic agents,
such as daunorubicine, trigger the anti-apoptotic functions of NF-κB [42–44]. This mechanism is
clinically important as many chemotherapeutical agents induce NF-κB, which consequently protects
cancer cells from cell dea h. This phenomenon has bee described in n mer us studies, for examp e
in cisplatin and camptothecin-treated lung cancer [45] and anthracycline- and taxane-treated breast
cancer [46]. These results led to the suggestion that targeting the anti-apoptotic role of NF-κB helps to
overcome therapy resistance [47]. Proof-of-concept studies showed that selective NF-κB inhibition
enhances the response to chemotherapy in gastric cancer [48] and IKK inhibition sensitizes melanoma
cells to doxorubicin-induced cell death [49]. Of note, in some settings, NF-κB can also trigger cell
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death, for example in response to oxidative stress [50] or in the execution of TRAIL- and CD95-
mediated apoptosis [51].
The role of NF-κB for replicative immortality is not well established, but an extensive crosstalk
between the telomerase catalytic subunit (TERT) and NF-κB has been described. TERT activity ensures
telomere elongation and thus helps to evade tumors from the fate of replicative senescence. NF-κB
p65 was found to modulate TNF-induced nuclear translocation as well as telomerase activity of
TERT in multiple myeloma cells [52]. The expression of the Tert gene is also directly upregulated by
NF-κB [53]. But, this regulation is mutual, as vice versa TERT directly regulates NF-κB-dependent gene
expression by binding to DNA-bound p65, potentially leading to hyperexpression of an extremely
tumor promoting set of genes [54].
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characteri tics of cancer. The relative thickness t e ar ows indicates the estimated relative
contributi n of NF-κB for the suppo t (arrow up) or a tagonism (arro down) for the
indicated processes.
Also, the activation of i asion and metast sis involves NF-κB-dependent proc sses. NF-κB plays
a significant role in the regulation of epithelial-mesenchy al transition (EMT), which is an early event
in metastasis [55]. Inhibition of NF-κB signaling by expression of a dominant negative IκBα prevents
EMT in Ras-transformed epithelial cells. This study also showed that NF-κB activation increases
the transition to a mesenchymal phenotype, while its inhibition in mesenchymal cells causes even
a reversal of EMT [56]. Collectively, these data suggest that NF-κB contributes both to the induction
and also the maintenance of EMT. TNF-triggered EMT depends on NF-κB-mediated upregulation
of Twist1, which is one of the key transcription factors modulating EMT [57]. In breast cancer cells,
NF-κB activation contributes not only to expression of Twist1, but also to further EMT-regulating
transcription factors, such as SLUG and SIP1 (Smad interacting pr tein 1) [58]. In addition, many cell
adhesion molecules, such as integ ins, selectins, ICAM-1 (intercellular adhesion molecule 1), E-selectin,
nd VCAM-1 (vascular cell adhesion molecule 1) are directly regulat d by NF-κB [59]. Th se molecul s
contribute to cancer cell extravasation, but NF-κB activity is also important in the non-tumorigenic
cells at the remote sites, which are colonized by tumor cells. This was shown in a mouse model of
metastasis where the injection of lung carcinoma cells results in a reduced formation of metastatic foci
in the livers of animals with a liver-specific deletion of IKKβ [60].
More recent evidence showed a contribution of NF-κB for the remodeling of tumor metabolism.
Tumor cells often (but not always) prefer to use glycolysis instead of oxidative phosphorylation,
as initially reported in 1927 by Otto Warburg [61]. The preferential use of glycolysis leads to a reduced
ATP production, but might allow tumor cells to survive under hypoxic conditions and also to
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deliver substrates and intermediates for various anabolic pathways [62]. The shift from oxidative
phosphorylation to glycolysis is mainly mediated by p53 and hypoxia inducible factor (HIF)-1, but also
NF-κB participates in this regulation. Knockdown of NF-κB p65 in mouse embryonic fibroblasts
causes cellular reprogramming to aerobic glycolysis, thus recapitulating the Warburg effect [63].
After glucose starvation, NF-κB p65 triggers p53 expression, which in turn leads to the mitochondrial
upregulation of cytochrome c oxidase 2 [63], which is a crucial component of the electron transport
chain. Another report showed that loss of p53 leads to p65-triggered expression of the glucose
transporter GLUT3 (glucose transporter 3) in tumor cells, resulting in increased glucose consumption
and anaerobic glycolysis [64]. The p65 protein can also be transported into the mitochondria in
the absence of p53. Mitochondrial p65 can associate with the mitochondrial genome to repress
mitochondrial gene expression and oxidative phosphorylation [65], and it will be interesting to study
the molecular mechanisms allowing p65 entry into the mitochondria.
NF-κB also sustains proliferative signaling, but this is seen only in specific cell types, such as
lymphocytes. An example for a direct and cell-specific effect of NF-κB is provided by mice that are
lacking the DNA-binding subunit c-Rel, which display defects in B-cell proliferation [66,67]. Similarly,
also RelB-deficient mice show defective proliferative responses in B cells [68]. In addition, Rel-/- mice
show reduced keratinocyte proliferation and epidermal thickness [69]. Growth inhibitory roles of
NF-κB have also been reported in mice expressing a dominant-negative IκBα protein. These mice
show hyperplasia of the epidermal epithelium, suggesting that NF-κB restricts the proliferation of this
cell type in vivo [70]. In addition to its importance for proliferation of specific cell types, NF-κB might
also be relevant for proliferation of cancer cells, although this aspect is not fully explored. For example,
RelB is required for proliferation of endometrioid adenocarcinoma [71] and overexpression of
dominant-negative IκBα interferes with the proliferation of cervix carcinoma cells [72].
Many solid tumors induce angiogenesis in order to ensure the supply of nutrients and oxygen
as well as to evacuate carbon dioxide and metabolic wastes [41]. This process is antagonized by
NF-κB, as revealed in a study using mice expressing a dominant-negative IκBα protein exclusively in
endothelial cells, resulting in the selective repression of NF-κB in endothelial cells. Inoculated tumors
grow faster and more aggressive in these transgenic mice, concomitant with a striking increase in
tumor vascularization [73]. Therefore, angiogenesis repression by NF-κB challenges the paradigm that
systemic NF-κB inhibition can serve as a universal anti-cancer strategy.
But, NF-κB also regulates two cancer enabling characteristics of cancer cells. The contribution
of NF-κB for tumor-promoting inflammation is very well documented and also covered by
a number of excellent reviews [74,75]. In order avoid repetition and redundancy, we refer to these
articles, which convincingly summarize how cells of the immune system create a tumor-promoting
microenvironment by the NF-κB-dependent production of growth and survival factors.
The enabling characteristics of cancer include the acquisition of genetic instability, which confers
selective advantage on cell subclones to enable their outgrowth and succession of clonal expansions [41].
NF-κB is activated by DNA damage, for example, by an ATM-mediated pathway in response to DNA
double strand breaks induced by oxidative stress. In addition, NF-κB also contributes to the repair of
double-strand breaks by homologous recombination. DNA damage triggers the association of p65 with
the CtIP-BRCA1 complex and thus stimulates DNA repair [76]. A role of NF-κB for genome stability
was revealed by the analysis of p65-deficient mouse and human cells, which show all of the signs of
genomic instability, including high frequencies of gene deletions, DNA mutations, and chromosomal
translocations [77]. The molecular mechanisms explaining the contribution of p65 for genomic stability
are not clear and need to be elucidated in the future.
In summary, numerous studies have revealed an important contribution of NF-κB to many aspects
of cancer biology. Although the majority of features are consistent with a tumor-promoting function of
this transcription factor, a global inhibition of NF-κB is not possible, as it would foster angiogenesis
and genetic instability.
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5.2. The Direct Roles of NF-κB in Cancer
The direct contribution of the NF-κB system to cancer is seen by the direct mutation of NF-κB
regulatory proteins [40]. Many of these mutations lead to lymphomas, which likely have its cause in
the important role of the NF-κB pathway in normal lymphocyte development and activation. A review
by Neil Perkins makes the important point that single mutations in NF-κB DNA-binding subunits
are relatively rare, as they cannot adequately mimic the diverse nature and complexity of the NF-κB
response [78]. Thus, the majority of NF-κB-driven cancers are induced by gain-of-function (GOF)
mutations in the upstream activators of NF-κB. While GOF mutations of upstream activators lead
to tumor formation that is dependent on the simultaneous induction of further signaling pathways,
mutations of the DNA-binding subunits can trigger oncogenesis without the requirement for additional
signals, as summarized in Figure 4.
The contribution of NF-κB for tumorigenesis by upstream activators is exemplified by mutations
that are found in components of the so-called CBM complex, which is essential for NF-κB activation in
lymphocytes by activation of the T-cell receptor (TCR) or B-cell receptor (BCR) [79]. The CBM complex
is composed of the scaffold protein CARMA1/CARD11 (CARD-MAGUK1/caspase recruitment
domain family member 11), the adaptor protein BCL10 (B-Cell CLL/lymphoma 10) and MALT1
(mucosa-associated lymphoid tissue lymphoma translocation protein 1), which has a dual role as
a scaffold protein and a paracaspase [80,81].
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Receptor activation leads to the recruitment of CARMA1 to lipid rafts, followed by its
phosphorylation, which induces a conformational change, thus allowing for its oligomerization,
the formation of BCL10 filaments and the attachment of MALT1 [82]. The BCL10/MALT1 filaments
are furt er decorated by the ubiquitin E3 lig se TRAF6, which likely results in the all-or-none
activation of the downstream pathways [82]. Active TRAF6 mediates the attachment of K63-branched
polyubiquitin chains at the C-terminus of MALT1, which allows for further protein/protein interactions
and the activation of NF-κB a d JNK/AP1 (c-Jun N-terminal kinase/activator protein 1) signaling.
The MALT1 protein has proteolytic activity and cleaves its substrate proteins after a positively charged
Biomedicines 2018, 6, 36 9 of 16
arginine residue in the P1 position [80,81]. Mutations leading to the constitutive activation of the
CBM complex are frequently found in lymphoid malignancies. GOF mutations of CARMA1 often
occur in diffuse large B-cell lymphoma, B-cell lymphoproliferative disorders, and also in T-cell
leukemia/lymphomas [83,84]. But, also the other members of the CBM complex are frequently
found to be mutated, overexpressed, or affected by chromosomal translocations (MALT1-API2 or
c-IAP2-MALT1). The GOF mutations of CBM members promote lymphomagenesis and MALT1
inhibitors have shown to allow for new treatment options for patients with refractory t(11;18)-positive
MALT1 lymphoma [85–87]. The constitutively active CBM complex leads to constant activation of
NF-κB and also to the permanent induction of the JNK/AP1 pathway and expression of RNA-binding
proteins (Roquin-1 and -2, Regnase-1), which mediate the stabilization of several NF-κB-dependent
transcripts. Of note, constitutive activation of NF-κB alone is not sufficient for lymphomagenesis
and requires further JNK-derived signals. This was revealed in a mouse model where the transgenic
expression of the constitutively active CARMA1 mutant CARMA1 (L225LI) is sufficient to trigger
aggressive B-cell lymphoproliferation. Inhibition of either NF-κB or JNK blocks proliferation of the
CARMA1 (L225LI)-expressing B-cells, showing that only cooperative NF-κB and JNK activation drives
the malignant growth [88].
While mutation of the upstream activators of NF-κB necessarily affects the co-regulatory pathways,
there is also evidence for an oncogenic function of the DNA-binding subunits, as summarized in
Figure 5. The DNA-binding subunits represent the endpoint of the NF-κB cascade and their ability
to mediate oncogenic transformation shows the importance of NF-κB-dependent transcriptional
programs. Soon after cloning of the avian retroviral protein v-Rel it became clear that retroviruses
encoding v-Rel are highly oncogenic and transform chicken cells in vitro and in vivo [89,90].
Transgenic mice expressing v-Rel in T-cells develop immature, multicentric aggressive T-cell
leukemia/lymphomas, showing that ectopic expression of v-Rel alone is sufficient for oncogenic
transformation [91]. Constitutive p50/v-Rel DNA-binding is induced upon v-Rel epression, but the
transforming activity also occurs in transgenic thymocytes lacking p50. The ability of v-Rel to trigger or
repress gene expression depends on the cell type [92], but v-Rel-mediated induction of gene expression
seems not to be as potent as gene induction by p65 [93]. Transformed chicken spleen cells show
v-Rel localization in the nucleus and also in the cytoplasm. [94], but a threshold nuclear level of
the v-Rel oncoprotein is required for the transformation of avian lymphocytes [95]. In the nucleus,
v-Rel cooperates with many transcription factors, such as the AP1 subunits c-Fos and c-Jun, IRF4,
and SP1 to mediate oncogenic transformation [96–98].
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From all five different DNA-binding subunits, only the v-Rel homologue c-Rel has the ability
to transform avian lymphoid cells dependent from the presence of both C-terminal TADs [99,100].
However, the removal of either of the 2 C-terminal TADs from c-Rel augments its transforming
activity, suggesting that a chronic low-level of transcriptional activation is optimal for oncogenic
transformation [101]. The c-Rel encoding REL locus is frequently altered (rearranged, amplified,
mutated) in a variety of B- and T-cell malignancies. The REL locus at the chromosomal position
2p16.1-15 is amplified in Hodgkin’s lymphoma (~46%) and diffuses large B cell lymphoma (DLBCL)
(~15%) [101]. Also, T-cell lymphomas (natural killer, peripheral T cells, anaplastic large cells) show
the frequent amplification of the REL locus [102]. Increased c-Rel expression has been observed in
Hodgkin lymphoma where the REL locus was found to be translocated to a position near the light chain
enhancer [103], or alternatively by integration of an EBV genome near to the c-Rel encoding region [104].
Experimental proof for a causative role of c-Rel overexpression in the process of tumorigenesis has
been obtained in a mouse model. Overexpression of c-Rel under the control of a hormone-responsive
mouse mammary tumour virus promoter led to the induction of mammary tumors, but these develop
with a long latency, suggesting the requirement of secondary events [105]. Also, nuclear localisation of
c-REL is frequently observed in cancer cells.
Furthermore, oncogenic fusion proteins have been described for c-Rel and p65. A chimeric
c-REL-ANKRD36 protein occurs in the RC-K8 DLBCL cell line due to a deletion on chromosome 2 [106].
Interestingly, the fusion partner ANKRD36 has several ankyrin repeats, which are also found in p100,
p105 and the IκB proteins. However, it is unclear whether this fusion protein is responsible for the
proliferation of the RC-K8 cells. Another oncogenic fusion protein, C11orf95-RELA, is expressed in
more than two-thirds of supratentorial ependymomas, a rare brain tumor, where C11orf95-RELA
accumulates in the nuclei [107]. A causative role of C11orf95-RELA for tumorigenesis was shown in
experiments where the expression of the fusion protein in mouse forebrain neural stem cells converted
them to brain tumor cells, probably by driving an aberrant transcription program [107]. The various
C11orf95-RELA fusion proteins contain one or two zinc finger domains, raising the possibility that this
fusion can alter the DNA-binding specificity of NF-κB. It will thus be interesting to characterize the
genomic binding sites of C11orf95-RELA and to compare them to the binding sites of the wildtype
p65 protein in healthy tissue. The finding that C11orf95-RELA expression generates only one highly
specific cancer type also illustrates the high plasticity and diversity of the NF-κB response.
6. Concluding Remarks
The NF-κB transcription factor system is of broad relevance for the formation and maintenance
of many tumor entities. Its broad relevance for central physiological processes does not allow for its
global inhibition and raises the need for the development of highly pathway-specific and cell-type
specific components as exemplified by MALT1 inhibitors, which are currently tested in clinical trials
for the treatment of lymphomas. Further work is needed in order to identify and characterize the
auxiliary components that help to specify and regulate the transcriptional output programs of NF-κB,
as these proteins could be additional druggable targets.
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